Telix Pharmaceuticals just boasted it's one step closer to getting a cancer treatment approved

Telix Pharmaceuticals Ltd (ASX:TLX) could hand investors huge gains or losses.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is now up 157% over 2019 from 65 cents at the turn of the year to a record high of $1.67 today and there could be more to come if the oncology researcher ever manages to commercialise any of its treatments for renal cancer, brain cancer, or metastatic prostate cancer. 

Today the company has fired up its supporters further by announcing that it had a "positive" meeting with the FDA the U.S. healthcare regulator over its plans to include "American patients into the ZIRCON Phase III study" for treating renal cancer. 

According to Telix, the FDA indicated that if its final Phase III study meets its scientific endpoint in demonstrating clinical efficacy under its proposed settings then this would be "supportive of a marketing authorisation" in the United States. 

Of course investors need to be aware that just because the FDA suggests the design of a trial is suitable for approval purposes does not mean the trial itself will be a success. 

In fact the local share market is littered with biotech businesses that have swallowed huge amounts of capital conducting expensive clinical trials into their products, without ever getting FDA or commercial approval elsewhere around the world.

This is a nice Segway onto the final point that Telix also requested a trading halt today ahead of a capital raising that the Australian Financial Review is reporting will see it ask investors to tip in another $40 million at a discounted $1.30 per share.

As at March 31 2019 the company had $17.68 million cash on hand and posted an operating cash loss of $7.4 million on product sales of just $0.7 million for the March quarter.

We can see then why the company is seeking a cash injection as bank debt is unlikely to be an option as bankers won't lend to cash sucking businesses unless they are all but certain they'll get their cash back with interest. 

The company has 150.9 million shares currently listed on the ASX with another 67.4 million subject to escrow until November 15, 2019. So based on 218.3 million shares outstanding it has a market value of $364 million with another $40 million about to be tipped in. 

Investors then are effectively betting that it will have some commercial success with its clinical stage trials. Whether or not it does is tough to know unless you have a professional expertise in oncology research and for this reasons among others I'm not a buyer of shares.

Other speculative biotechs investing heavily in research include Mesoblast Limited (ASX: MSB) and newly-listed Invex Therapeutics Ltd (ASX: IXC). 

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Broker gives its verdict on BHP shares

Let's see what Bell Potter is saying about the Big Australian.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Woman holding gold bar and cheering.
Gold

Why Macquarie expects this surging ASX 200 gold stock could leap another 40%

Macquarie forecasts another year of strong outperformance from this fast-rising ASX 200 gold miner.

Read more »

A young woman looks at here phone as she strides out in an airport dragging her wheelie bag behind her and smiling widely.
Broker Notes

Macquarie tips 15% upside for this ASX 200 industrials stock

Is this transportation business preparing for take-off?

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another momentous session for ASX shares this Friday.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher

These shares are ending the week with a bang. But why?

Read more »

Disappointed man with his head on his hand looking at a falling share price his a laptop.
Share Fallers

Why 29Metals, Atlas Arteria, DroneShield, and Yancoal shares are falling today

Let's see why these shares are ending the week in the red.

Read more »